


AD-A042 131

ARMY MEDICAL RESEARCH INST OF INFECTIOUS DISEASES FR--ETC F/G 6/1
THE ROLE OF INFLAMMATION IN ZINC, AMINO ACID AND PROTEIN ALTERA--ETC(U)
JUN 77 M C POWANDA, R E DINTERMAN, E C HAUER

UNCLASSIFIED

NL

| OF |
AD
A042131



END

DATE
FILMED
8-77

AD A 042131

See 1473

2

The Role of Inflammation in Zinc, Amino Acid
and Protein Alterations Induced by Zinc Chloride

MICHAEL C. POWANDA, RICHARD E. DINTERMAN, EDWARD C. HAUER AND
PHILIP Z. SOBOCINSKI

United States Army Medical Research Institute of Infectious Diseases
Fort Detrick, Frederick, Maryland 21701

RUNNING TITLE: INFLAMMATION INDUCED BY IP $ZnCl_2$

CATEGORY: Pathology

In conducting the research described in this report, the investigators adhered to the "Guide for the Care and Use of Laboratory Animals," as promulgated by the Committee on the Revision of the Guide for Laboratory Animal Facilities and Care of the Institute of Laboratory Animal Resources, National Research Council. The facilities are fully accredited by the American Association for Accreditation of Laboratory Animal Care.

The views of the author do not purport to reflect the positions of the Department of the Army or the Department of Defense.

Approved for public release - distribution unlimited

21 June 1977

AD No. —
DDC FILE COPY

J D C
RECEIVED
JUL 28 1977

F

Address all correspondence to:

Dr. Michael C. Powanda
Biochemistry Branch/USAISR
Fort Sam Houston
San Antonio, Texas 78234

Address reprint requests to:

Dr. Michael C. Powanda
c/o Commander
USAMRIID
Frederick, MD 21701

DISSEMINATION for	
NTIS	V. Section <input checked="" type="checkbox"/>
DDC	B. Section <input type="checkbox"/>
UNANNOUNCED	<input type="checkbox"/>
RESTRICTION	<input type="checkbox"/>
BY	
DISTRIBUTION/PRIORITY CODES	
SPECIAL	
A	

Zinc therapy has been advocated by Chvapil to ameliorate certain aspects of selected inflammatory diseases based on the hypothesis that zinc contributes to the stability of membranes (1). Zinc sulfate given per os has in fact been used in patients to treat ulcers (2) and rheumatoid arthritis (3) with some indication of mild success. In rats, zinc chloride administered ip, is effective in muting the toxicity of endotoxin (4) or alcohol (5) when these agents are also administered ip. The protection afforded by zinc against the lethal effects of endotoxin appears to be limited to the case where endotoxin is administered ip and involves, in some as yet undefined manner, reduction in the absorption of the toxin from the peritoneal cavity (4). We have also recently observed that concomitant ip injections of $ZnCl_2$ have a differential effect as regards the lethality of bacterial infections in rats, enhancing the mortality of murine typhoid but both slowing the onset of death and somewhat muting the mortality due to tularemia and pneumococcal sepsis (6). In light of the above findings in rats and the potential use of zinc salts in the treatment of certain inflammatory diseases in patients, we thought it advisable to ascertain what are the effects of zinc salts themselves on the host. We directed our attention to the effects of ip injections of varying amounts of $ZnCl_2$ on amino acid and plasma protein metabolism because zinc has been implicated as a co-factor in the metabolism of certain amino acids and the synthesis of proteins (7, 8).

Materials and methods. Fisher-Dunning male rats, 200-225 g (Microbiological Associates, Walkersville, Md.) were used in all studies and were fasted after the injection of zinc chloride or, in the case of the controls, physiological saline. Zinc chloride (Fisher Scientific, Fairlawn, N.J.) was dissolved in sterile saline. Plasma and tissue zinc content was determined by atomic absorption spectrophotometry (9). The tissue samples (1 g) were solubilized by the addition of 1 ml of 25% tetramethylammonium hydroxide (10). To assess amino acid transport the rats were injected sc with 1 μ Ci [14 C]aminoisobutyric acid/100 g body weight 24 hr prior to the injection of zinc chloride or saline (11). Phenylalanine and tyrosine concentration in plasma were determined using a Beckman model 121 M amino acid analyzer (Beckman Instruments, Silver Spring, Md.). Plasma glucagon and insulin were measured by double antibody radioimmunoassay (12). Plasma seromucoid was determined according to the procedure of Neuhaus *et al.* (13); α_2 -macroglobulin by radial immunoassay (14). Plasma β -glucuronidase activity was measured as described previously (4). Total white blood cell count was determined with a Coulter counter and the differential by counting 100 white cells in thin smears. Statistical significance was assessed by analysis of variance.

Results. The plasma zinc concentration at 5 hr after ip injection of $ZnCl_2$ is a curvilinear function of the dose administered with a significant increase versus controls at 8 and 16 mg/kg body weight (Fig. 1A). In contrast, hepatic zinc content is a linear function of the dose, while skeletal muscle content remains unchanged (Fig. 1B). Amino acid uptake by liver and muscle,

approximated by the [^{14}C]aminoisobutyrate (AIB) content of these tissues is depicted in Fig. 2. There was an increased uptake of ^{14}C -AIB into liver 5 hr after ip injection of either 8 or 16 mg/kg ZnCl_2 . Muscle on the other hand displayed a slight, albeit statistically significant, decrease in ^{14}C -AIB content at 2, 4 and 16 mg/kg. The insert in the upper left corner of the figure indicates that there were no statistically significant alterations in peripheral plasma glucagon or insulin for any dose of zinc at 5 hr. Another evidence of altered amino acid distribution or metabolism is the plasma phenylalanine/tyrosine (P/T) ratio. There is a significant increase in the plasma P/T ratio at 4, 8, and 16 mg ZnCl_2 (Table I).

Evidence of tissue damage and/or inflammation 5 hr after the ip injection of varying amounts of ZnCl_2 are also presented in Table I. There is a significant increase in the percent neutrophils in the blood at 4-16 mg of ZnCl_2 but no change in total white blood cell count. There is an increase in plasma β -glucuronidase activity but only at the 4 mg/kg dose of ZnCl_2 . There is histologic evidence of localized inflammation in 25% of the livers taken from animals given 8 mg and in 100% of the livers taken from animals given 16 mg ZnCl_2 .

Twenty-four hours after the ip injection of varying amounts of ZnCl_2 , plasma zinc concentrations was still significantly above control values in those animals given 8 or 16 mg (Table II). In contrast to 5 hr postinoculation, all rats receiving zinc displayed significant decreases in total white cell count, but only those which had received 8 or 16 mg zinc showed an increase in percent neutrophils. There was a small but significant increase in seromucoid concentration at 24 hr after 8 or 16 mg of ZnCl_2 .

Alpha₂-macroglobulin was detectable in the plasma of those rats receiving 4-16 mg of ZnCl₂ with greater levels of this fetal globulin being found at the higher doses of zinc.

Discussion. Zinc salts are well known for their irritant properties. Thus, it is surprising that on the one hand zinc salts may, in certain well-defined instances, be of potential therapeutic value (2,3) and on the other that these irritant properties are overlooked in experiments involving the parenteral administration of zinc salts. This paper presents evidence that the ip injection of ZnCl₂ produces systemic manifestations of inflammation comprised of (but not necessarily limited to) neutrophilia, zinc and amino acid redistribution and alterations in plasma protein concentration.

Neutrophilia is not uncommon during infection and inflammation and can be produced in healthy animals by the injection of a factor (or factors) derived from leukocytes (15,16). A decrease in plasma zinc concentration and an increase in hepatic zinc content have been demonstrated during inflammation and infection (17,18) and also can be elicited by leukocytic derived factors (LEM) (19). The uptake of zinc by liver presumably involves the formation of metallothionein (20,21); there is evidence that hepatic synthesis metallothionein-like proteins can be induced by LEM (22). Increased amino acid transport into liver has been observed during a number of infections (11,18) and inflammation (17) and also can be elicited by the injection of LEM (23). An increase in the serum phenylalanine tyrosine ratio has been detected during a wide variety of infections in man and experimental animals and can be produced by the repeated injection of LEM (24-27). Increased plasma seromuroid concentration

and the detectable presence of α_2 -macroglobulin in the plasma occurs during inflammation and infection (17,18,26) and in response to LEM (28).

The ip injection of 4-16 mg of zinc chloride in sterile saline elicits all of the above reactions, neutrophilia, amino acid and zinc uptake by liver, increased plasma phenylalanine tyrosine ratio and both increased seromucoid concentration and the presence of α_2 -macroglobulin in the plasma. The occurrence of all these systemic sequelae and indices of inflammation are consonant with the known irritant properties of zinc salts.

Moreover, the presence of hepatic capsulitis in those animals receiving the 8 and 16 mg doses of $ZnCl_2$ indicate localized inflammation. The significant increase in plasma β -glucuronidase activity at the 4-mg dose of $ZnCl_2$ is consistent with tissue damage, particularly liver (29). Considering the presence of capsulitis at 8 and 16 mg of $ZnCl_2$ the absence of additional increases in plasma β -glucuronidase is surprising, but considering the proposed role of zinc in stabilizing membranes (1) may not be totally unexpected. It is conceivable that although the higher concentrations of $ZnCl_2$ induce a greater degree of inflammation, they also reduce the release of certain lysosomal enzymes. Finally, although increases in glucagon and insulin have been implicated in the enhanced uptake of amino acids by liver produced by LEM (30) these hormones appear not to be operative in this instance, in that no significant alterations in either hormone are detectable at any of the doses of zinc chloride.

To what degree these metabolic and physiologic sequelae, as well as LEM itself, play a role in the protective (4,5,31-33) activities attributed to zinc remain to be assessed. For example, it has been proposed that certain of the metabolic alterations which do occur during infections, presumably a result of LEM, may be of benefit to the host (34). Also, it is not clear to what extent the induction of hepatic and intestinal metallothionein (21,35) or α -aminolevulinic acid dehydratase in red blood cells (36) is a direct effect of zinc itself or an indirect effect arising from the inflammatory properties of zinc salts. This is not to say that all of the consequences of injection of zinc salts can be ascribed to inflammation and are mediated by LEM, but rather that inflammation and LEM must be taken into consideration when zinc salts (or other potential irritants) are administered parenterally.

Summary

The ip injection of zinc chloride (4-16 mg/kg) produces a curvilinear increase in plasma zinc concentration, a linear increase in liver zinc content, and an increase in the hepatic uptake of [14 C]aminoisobutyrate which are significantly greater than control values. This dose range of $ZnCl_2$ also produces neutrophilia, increases in the plasma phenylalanine/tyrosine ratio and seromuroid and the appearance of α_2 -macroglobulin in the plasma, all of which are indicative of inflammation. It is suggested that some of the protective and metabolic effects ascribed to zinc may in fact be the result, at least in part, of the inflammation which occurs when zinc salts are injected ip.

References

1. Chvapil, M., *Med. Clin. N. Am.* 60, 799 (1976).
2. Frommer, D. J., *Med. J. Aust.* 2, 793 (1975).
3. Simkin, P. A., *Lancet* 2, 539 (1976).
4. Sobocinski, P. Z., Powanda, M. C., Canterbury, W. J., Machotka, S. V., Walker, R. I., and Snyder, S. L., *Infect. Immun.* 15, 950 (1977).
5. Yunice, A. A., and Lindeman, R. D., *Proc. Soc. Exp. Biol. Med.* 154, 146 (1977).
6. Sobocinski, P. Z., Powanda, M. C., and Canterbury, W. J., *Proc. Soc. Exp. Biol. Med.* In press, (1977).
7. Hsu, J. M., Anthony, W. L., and Buchanan, P. J., *Proc. Soc. Exp. Biol. Med.* 127, 1048 (1968).
8. Hsu, J. M., Anthony, W. L., and Buchanan, P. J., *J. Nutr.* 99, 425 (1969).
9. Pekarek, R. S., Beisel, W. R., Bartelloni, P. J., and Bostian, K. A., *Am. J. Clin. Pathol.* 57, 506 (1972).
10. Murthy, L., Mender, E. E., Eller, P. M., and Petering, H. G., *Anal. Biochem.* 53, 365 (1973).
11. Wannemacher, R. W., Jr., Powanda, M. C., and Dinterman, R. E., *Infect. Immun.* 10, 60 (1974).
12. Rocha, D. M., Santeusanio, F., Faloona, G. R., and Unger, R. H., *N. Engl. J. Med.* 288, 700 (1973).
13. Neuhaus, O. W., Balegno, H. F., and Chandler, A. M., *Am. J. Physiol.* 211, 151 (1966).
14. Weimer, H. E., and Benjamin, D. C., *Am. J. Physiol.* 209, 736 (1965).

15. Kampschmidt, R. F., Upchurch, H. F., Eddington, C. L., and Pulliam, L. A., *Am. J. Physiol.* 224, 530 (1973).
16. Mapes, C. A., and Sobocinski, P. Z., *Am. J. Physiol.* 232, C15 (1977).
17. Powanda, M. C., Cockerell, G. L., and Pekarek, R. S., *Am. J. Physiol.* 225, 399 (1973).
18. Powanda, M. C., Cockerell, G. L., Moe, J. B., Abeles, F. B., Pekarek, R. S., and Canonico, P. G., *Am. J. Physiol.* 229, 479 (1975).
19. Pekarek, R. S., Wannemacher, R. W., Jr., and Beisel, W. R., *Proc. Soc. Exp. Biol. Med.* 140, 685 (1972).
20. Chen, R. W., Eakin, D. J., and Whanger, P. D., *Nutr. Rep. Int.* 10, 195 (1974).
21. Richards, M. P., and Cousins, R. J., *Biochem. Biophys. Res. Commun.* 64, 1215 (1975).
22. Sobocinski, P. Z., Canterbury, W. J., and Mapes, C. A., *Fed. Proc.* 36, 1100 (1977).
23. Wannemacher, R. W., Jr., Pekarek, R. S., and Beisel, W. R., *Proc. Soc. Exp. Biol. Med.* 139, 128 (1972).
24. Newberne, P. M., *fed. Proc.* 25, 1701 (1966).
25. Powanda, M. C., Dinterman, R. E., Wannemacher, R. W., Jr., and Herbrandson, G. D., *Biochem. J.* 144, 173 (1974).
26. Powanda, M. C., Kenyon, R. H., and Moe, J. B., *Proc. Soc. Exp. Biol. Med.* 151, 804 (1976).
27. Wannemacher, R. W., Jr., Klainer, A. S., Dinterman, R. E., and Beisel, W. R., *Am. J. Clin. Nutr.* 29, 997 (1976).

28. Pekarek, R., Wannemacher, R., Powanda, M., Abeles, F., Mosher, D., Dinterman, R., And Beisel, W., *Life Sci.* 14, 1765 (1974).
29. Canonico, P. G., Powanda, M. C., Cockerell, G. L., and Moe, J. B., *Infect. Immun.* 12, 42 (1975).
30. George, D. T., Abeles F. B., Mapes, C. A., Sobocinski, P. Z., Zenser, T. V., and Powanda, M. C., *Am. J. Physiol.* in press (1977).
31. Chvapil, M., Ryan, J. N., Elias, S. L., and Peng, Y. M., *Exp. Molec. Pathol.* 19, 186 (1973).
32. Chvapil, M., and Owen, J. A., *J. Molec. Cell Cardiol.* 9, 151 (1977).
33. Phillips, J. L., and Sheridan, P. J., *J. Nat. Cancer Inst.*, 57, 361 (1976).
34. Powanda, M. C., *Am. J. Clin. Nutr.* in press (1977).
35. Richards, M. P. and Cousins, R. J., *Biochem. Biophys. Res. Commun.* 75, 286 (1977).
36. Abdulla, M., Haeger-Aronsen, B., and Svensson, S., *Enzyme* 21, 248 (1976).

TABLE 1

Evidences of inflammation at 5 hours

Mg ZnCl ₂ kg body wt	Mean + SEM			
	Phenylalanine Tyrosine	% Neutrophils	β -glucuronidase μ g/dl	Histology
0 (saline)	0.99 ± 0.03	24 ± 2	63 ± 6	-
1	1.19 ± 0.07	22 ± 3	57 ± 5	-
2	1.23 ± 0.06	22 ± 2	64 ± 4	-
4	1.47 $\pm 0.05^{**}$	39 $\pm 3^{**}$	101 $\pm 8^{**}$	-
8	1.70 $\pm 0.05^{**}$	34 $\pm 2^*$	82 ± 2	hepatic capsulitis 2/8
16	1.72 $\pm 0.03^{**}$	53 $\pm 2^{**}$	84 ± 6	hepatic capsulitis 6/6

*P < 0.01, **P < 0.001 vs saline.

TABLE 2

Evidence of inflammation at 24 hours

Mg ZnCl ₂ kg body wt	Zinc μg/dl	Total WBC x10 ⁶ /mm ³	% Neutrophils	Seromucoid mg/dl	α ₂ -macrofetoglobulin units/ml
0	127 + 3	7.4 +0.6	15 + 1	372 + 19	0
1	135 + 3	5.0 +0.2**	17 + 1	345 + 24	0
2	148 + 5	4.9 +0.2**	16 + 1	350 + 11	0
4	153 + 5	5.5 +0.1**	15 + 2	378 + 10	1.4 +0.2
8	173 + 6*	5.5 +0.4**	34 + 2**	476 + 15**	3.6 +0.3
16	252 + 24**	5.8 +0.1*	38 + 2**	478 + 34**	6.2 +1.5

*P < 0.01; **P < 0.001.



LEGENDS TO FIGURES

Figure 1a. - Plasma zinc concentration.


1b. - Liver and skeletal muscle zinc concentration.

Figure 2. - [^{14}C]Aminoisobutyrate content in liver and skeletal muscle.

Insert: Plasma glucagon and insulin concentrations.




TISSUE [¹⁴C]AIB CONTENT



■ LIVER
 ● MUSCLE
 * P < 0.01
 ** P < 0.001
 } VS SALINE

mg ZnCl₂ /kg BODY WEIGHT



UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM	
1. REPORT NUMBER	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER	
4. TITLE (and Subtitle) The Role of Inflammation in Zinc, Amino Acid and Protein Alterations Induced by Zinc Chloride.		5. TYPE OF REPORT & PERIOD COVERED Interim report	
7. AUTHOR(s) Michael C. Powanda, Richard E. Dinterman, Edward C. Hauer and Philip Z. Sobocinski		6. PERFORMING ORG. REPORT NUMBER	
9. PERFORMING ORGANIZATION NAME AND ADDRESS U.S. Army Medical Research Institute of Infectious Diseases, SCR D-UIP-S Fort Detrick, Frederick, MD 21701		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS 61102B 3M161102BS03 00 009	
11. CONTROLLING OFFICE NAME AND ADDRESS U.S. Army Medical Research and Development Command, Office of the Surgeon General Department of the Army, Washington, DC 20314		12. REPORT DATE 21 June 1977	
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office) 12 18p		13. NUMBER OF PAGES 13 + 2 figures	
		15. SECURITY CLASS. (of this report) Unclassified	
16. DISTRIBUTION STATEMENT (of this Report) Approved for public release - distribution unlimited		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE	
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)			
18. SUPPLEMENTARY NOTES Reprints bearing assigned AD number will be forwarded upon receipt. To be published in PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE.			
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) Zinc chloride Plasma proteins Inflammation Rats, Zinc Amino acids → C(14)			
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) The ip injection of zinc chloride (4-16 mg/kg) produces a curvilinear increase in plasma zinc concentration, a linear increase in liver zinc content, and an increase in the hepatic uptake of ¹⁴ C aminoisobutyrate which are significantly greater than control values. This dose range of ZnCl ₂ also produces neutrophilia, increases in the plasma phenylalanine/tyrosine ratio and seromucoid and the appearance of alpha ₂ -macroglobulin in the plasma, all of which are indicative of inflammation. It is suggested that some of the protective and metabolic effects ascribed to zinc may in fact be the result, at least in part,			

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE(When Data Entered)

of the inflammation which occurs when zinc salts are injected ip.



UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE(When Data Entered)